CC
CBIO

Caxton Corporation’s Crescent Biopharma CBIO Stock Holding History

Caxton Corporation’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,036
Closed -$50.9K – 13
2024
Q4 		$50.9K Buy
+2,036
New +$55.5K 0.31% 13
2020
Q2 		– Sell
-151
Closed -$34K – 19
2020
Q1 		$34K Sell
151
-106
-41% -$40.5K 0.04% 17
2019
Q4 		$136K Sell
257
-9
-3% -$4.87K 0.13% 39
2019
Q3 		$115K Buy
+266
New +$171K 0.13% 39

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caxton Corporation's CBIO Position: Q1 2025 in Review

Caxton Corporation sold out of Crescent Biopharma (CBIO) in Q1 2025, closing a stake of 2,036 shares — an estimated $50.9K sold.

Caxton Corporation first reported a position in CBIO in Q3 2019 and held it in 4 quarters. The position peaked at $136K in Q4 2019. 35 funds tracked by Wall St. Rank hold CBIO as of Q1 2025.

  • Caxton Corporation reported no remaining Crescent Biopharma position as of Q1 2025 after selling out during the quarter.
  • Caxton Corporation sold 2,036 Crescent Biopharma shares in Q1 2025, an estimated $50.9K.
  • Caxton Corporation first reported a position in Crescent Biopharma in Q3 2019 and held it in 4 quarters.
  • Caxton Corporation's Crescent Biopharma position peaked at $136K in Q4 2019.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2025.

Based on Caxton Corporation's 13F filing for Q1 2025, filed 15 May 2025.